Artigo 01
Artigo 01
Artigo 01
Effectiveness of non-pharmacological
interventions for insomnia in children with
Autism Spectrum Disorder: A systematic
review and meta-analysis
Sophie Keogh1☯, Christopher Bridle2‡, Niroshan A. Siriwardena2‡, Amulya Nadkarni1,
Despina Laparidou ID2‡, Simon J. Durrant2, Niko Kargas2, Graham R. Law2,
Ffion Curtis ID2☯*
1 Lincolnshire Partnership Foundation Trust, Lincoln, United Kingdom, 2 Lincoln Institute for Health,
University of Lincoln, Lincoln, United Kingdom
a1111111111
a1111111111 ☯ These authors contributed equally to this work.
a1111111111 ‡ These authors also contributed equally to this work.
* [email protected]
a1111111111
a1111111111
Abstract
Conclusions
There are very few high quality randomised controlled trials in this area. Here we provide ini-
tial synthesised quantitative evidence of the effectiveness of behavioural interventions for
treating sleep problems in children with ASD.
Trial registration
Protocol was registered (CRD42017081784) on the International Prospective Register of
Systematic Reviews (http://www.crd.york.ac.uk/PROSPERO).
Background
Autism spectrum disorders (ASD) are a set of neurodevelopmental disorders characterised by
behavioural, communication and social impairments [1]. Worldwide it is estimated that 1 in
160 children has an ASD [2]. Disordered sleep is one of the most common reasons parents
seek medical support [3], with 40–80% of children with ASD having sleep difficulties [4].
Behaviours associated with disordered sleep in ASD include difficulty self-settling, frequent
night waking, greater sleep onset latency, early waking and poor sleep efficiency (ratio of total
sleep time to total time spent in bed) [4]. Disordered sleep can exacerbate some of the symp-
toms of ASD, such as over activity, disruptive behaviour, communication difficulties, repetitive
behaviours and social skill deficits, which is not only impairing for the child, but will also
increase family/caregiver stress [5, 6]. There are also lasting effects as adequate quantity and
quality of sleep during childhood years is essential for neuronal development, which deter-
mines long-term trajectories of behaviour, learning, health and wellbeing [7].
In 2017, Cuomo et al. [7] conducted a meta-synthesis of eight reviews examining the effi-
cacy of various sleep interventions, including pharmacologic treatments, alternative therapies
and behavioural interventions, in children with ASD. Two of the included reviews [1, 8]
focused on behavioural interventions in children with ASD, identifying a total of 15 studies.
Overall Cuomo et al. [7] concluded that parent education and behavioural interventions
showed the most promise for the treatment of multiple sleep problem domains. More recently,
Kilpatrick et al. [9] conducted a systematic review of the literature focusing on the efficacy of
parent training incorporated in behavioural sleep interventions for children with ASD and/or
intellectual disabilities. They concluded that the inclusion of parent training within beha-
vioural sleep interventions was considered generally effective, was valued by parents, and 9 of
the 11 studies reported a reduction in sleep problems. These reviews included a broad range of
studies (different research designs, diverse sample populations, a variety of intervention types,
and a range of outcome measures), so the review authors [7, 9] were able to maximize the use
of the evidence available; however, this was also limiting, as it was not possible to then statisti-
cally quantify intervention effects (e.g. a meta-analysis).
Sleep research is a rapidly developing area with emerging evidence indicating that sleep dis-
turbances are not merely consequences of disease, but play important roles in their develop-
ment [10]. Improving sleep outcomes is considered a priority in children with ASD, where
development is already compromised [11]. The evidence for pharmacological interventions
such as melatonin is inconclusive, reporting mixed findings in relation to dose, effectiveness
and side-effects [12]. The National Institute for Health and Care Excellence [13] recommend
that behavioural interventions are first line treatment for insomnia in ASD. Pharmacological
interventions are only to be considered if sleep problems persist despite following the sleep
plan (behavioural intervention), and are still only to be prescribed in conjunction with non-
pharmacological interventions. Importantly, parents consider behavioural interventions as
preferable to, and as effective as, medication [14]. Consequently, there is growing interest in
the development of effective non-pharmacological interventions for treating insomnia. This is
of particular importance in children with ASD and so supports the need to confirm the effec-
tiveness of behavioural interventions in this population.
The aim of this review was to provide an up-to-date synthesis of the available evidence,
focusing on behavioural interventions targeting sleep problems, compared to no intervention,
in children with ASD.
Methods
The inclusion criteria and methods of analysis were specified in advance and documented in a
protocol that was registered (CRD42017081784) on the International Prospective Register of
Systematic Reviews (http://www.crd.york.ac.uk/PROSPERO). This review was reported in
accordance with the Preferred Reporting Items for Systematic review and Meta-Analysis’
(PRISMA) guidelines [15] (S1 PRISMA Checklist).
Eligibility criteria
Studies were considered for inclusion if they were randomised controlled trials (RCTs) of
sleep-based behavioural interventions for children with ASD. In order for a study to be consid-
ered for inclusion the sample would have to be children aged 18 years or under. The review
included studies in which participant eligibility required a pre-existing diagnosis of ASD. Stud-
ies of behavioural interventions targeting sleep compared with concurrent control that
reported relevant sleep outcome measures were eligible. Behavioural interventions were
defined as an intervention which uses behavioural techniques, such as reinforcement to sup-
port the desired behaviour.
Study identification
To identify existing relevant systematic reviews, published, unpublished and ongoing trials,
the following electronic databases were searched from inception to January 2019: MEDLINE,
PsycINFO, CINAHL, ScienceDirect, Web of Science, Autism Data, CENTRAL, ClinicalTrials.
gov and Current Controlled Trials. No restrictions on language were imposed. Database
searching was supplemented with internet searching (e.g. Google Scholar), and forward and
backward citation tracking from systematic reviews and included studies. Key search terms for
database searching included the following:
("Autism spectrum disorder" OR asd OR autism) AND (sleep OR insomnia OR "bedtime resis-
tance" OR dyssomnia) AND (child OR toddler OR infant OR adolescent OR preschool OR
teenage OR pediatric OR paediatric OR childhood)
Search terms used in the MEDLINE search are provided in Supplementary Material: S1
Electronic Search Strategy.
Search results were downloaded to Endnote, and duplicate citations were removed. Two
reviewers independently screened titles and abstracts against the inclusion criteria. Where
studies could not be excluded based on title and abstract, two reviewers independently assessed
full papers for relevance. Any discrepancies were resolved through discussion or, where
required, through involvement of a third reviewer.
Data abstraction
Data were extracted by one reviewer and checked for accuracy by another using a template
that included: (a) study details, for example title, aim, design and type of intervention; (b) par-
ticipant information, for example age, gender, diagnosis, severity, co-morbidities and inclu-
sion/exclusion criteria; (c) groups, for example number randomised, description of
intervention and comparator, delivery, content, frequency, duration and provider; (d) out-
comes, for example primary outcome name, definition, type, how it is measured and reported,
missing data and reasons for missing data.
Data analysis
All analyses were conducted using Review Manager (RevMan) version 5.3 [16] software for
Windows. All studies reported changes in sleep as a continuous outcome. The primary out-
come was a mean difference in total sleep duration (actigraphy data), which was reported in 3
studies [17]. Secondary outcomes included sleep latency and sleep efficiency (actigraphy data),
and total score from the CSHQ [18]. The summary measure of treatment effect for both pri-
mary and secondary outcomes was the between groups difference in sleep outcomes, expressed
as mean difference (MD).
Random-effects models were used in all meta-analyses, as they are more conservative than
the fixed effects models since, by incorporating within- and between-study variance, the confi-
dence intervals for the summary effect are wider. Statistical heterogeneity was assessed using
the I2 test, which described the percentage of variability among effect estimates beyond that
expected by chance. In cases where heterogeneity was considered to be important (I2 values
�40%), sources of clinical and methodological diversity were explored.
Results
After removal of duplicate citations, the search strategy identified 3,505 distinct citations, of
which 3,453 were excluded during the initial screening phase (Fig 1). For the remaining 52
citations, full text papers were ordered. Three studies met the inclusion criteria [17, 19, 20].
The main reasons for exclusion of full text papers were study design (n = 33), outcome mea-
sures (n = 5), and intervention (n = 11).
2000) and confirmed by the Autistic Diagnostic Interview–Revised (ADI-R) and/or the
Autism Diagnostic Observation Schedule–generic (ADOS-G). In the third study, a clinician
diagnosis of an ASD was confirmed by parents of the participants [20].
To identify sleep problems in participating children, two studies [17, 19] used parental
report of sleep difficulties, including consideration of sleep onset latency, wake after sleep
onset or night-time awakenings. The third study required participants to have sleep onset dis-
order, limit setting disorder, delayed sleep phase or insomnia as defined by the American
Academy of Sleep Medicine [20].
Common participant exclusion criteria in the individual studies included current receipt of
pharmacological treatments, psychotherapy or a behavioural intervention, sleep disordered
breathing [19], Periodic Limb Movement [19], serious medical or mental health conditions
[20], and sleep apnea [17, 20].
Delivery of behavioural interventions varied across the different studies. Adkins et al. [17]
provided an education pamphlet for parents to read and follow without further instruction
from the study staff. Experienced clinical psychologists delivered four-weekly 50-minute face-
to-face CBT sessions in the Cortesi et al. [19] study. This was delivered in an outpatient univer-
sity clinic and completion was defined as completion of the baseline session and at least two
treatment sessions. Papadopoulos et al. [20] used two face-to-face sleep consultations and a fol-
low-up phone call with a trained clinician, each two weeks apart, to deliver their intervention.
This study also provided the most details in relation to sleep disorders, definitions and
https://doi.org/10.1371/journal.pone.0221428.t001
examples of behavioural interventions (e.g. sleep onset association disorder, child associates
falling asleep with a certain objector person which would be addressed by Parental presence at
sleep time being managed with adult fading/graduated extinction).
All studies were two-arm design RCTs (intervention vs control) with the exception of Cor-
tesi et al. [19], who investigated the relative and combined effects of melatonin and CBT,
compared to a placebo control (four-arm). Primary outcomes for the included studies were
sleep measures; actigraphy data [17], CSHQ scores [20] or both actigraphy data and CSHQ
scores [19].
Of the 28 participants in the intervention group of the Papadopoulos et al. [20] study, 26
were taking medications such as Ritalin, Concerta, or Clonidine. In the control group, 27 of
the 33 participants were taking medications: Ritalin, Concerta, and Atomexetine. Five children
in the intervention group (n = 18) in the Adkins et al. [17] study were taking psychotropic
medications, three were taking melatonin and two stimulants. Within the control group
(n = 18), nine were taking psychotropic medications, three melatonin and two stimulants. All
children in the Cortesi et al. [19] study were drug free for at least six months and no children
receiving psychotherapy or behavioural interventions were enrolled in the study.
Of the two studies [17, 19] that used actigraphy devices to measure sleep outcomes, data for
total sleep time measured in minutes (Fig 2), sleep onset latency (time from lights out to mea-
sured first sleep onset) (Fig 3), and sleep efficiency (ratio of total sleep time to total time in
bed) (Fig 4) were available for statistical analysis. Adkins et al. [17] collected actigraphy data
via AW Spectrum Acti-watch devices (Phillips Respironics, Bend, OR) for two weeks following
a 2-week pamphlet intervention period. Cortesi et al. [19] monitored each child with an acti-
graphy device in the zero crossing mode from the Ambulatory Monitoring Inc. (Ardsley, NY,
USA) for a minimum of seven nights following 12 weeks of CBT. Actigraphy devices were
used in conjunction with parent report sleep diaries in both of the studies. Adkins et al. [17]
used the devices to confirm parent report and Cortesi et al. [19] recommended parents kept
diaries to enable editing of actigraphy data for potential artefacts and failures.
Two studies [19, 20] reported outcome data using the CSHQ. This is a standardised ques-
tionnaire designed for use in children. It includes 45 items and is rated retrospectively over the
previous week to screen for common sleep problems in key areas such as child bedtime, sleep
behaviour and night time waking. Both studies reported a total sleep disturbance score for the
questionnaire, which was used for the pooled data synthesis (Fig 5). A total score of 41 is con-
sidered the optimal clinical cut-off for sleep disturbance [18].
Meta-analysis of two studies [17, 19] demonstrated a statistically significant increase in total
sleep time following behavioural sleep interventions (Fig 2, 24.41, 95% CI 5.71, 43.11,
P = 0.01). There was no indication of statistical heterogeneity among the studies reporting
total sleep time (I2 = 0%). The synthesised data from these two studies also demonstrated a sig-
nificant between groups mean difference (-18.31, 95% CI -30.84, -5.77, P = 0.004) in sleep
onset latency, favouring the intervention group (Fig 3). When sleep efficiency (%) data from
the two studies were synthesised, a statistically significant effect was observed on sleep efficiency
following a behavioural sleep intervention (5.59, 95% CI 0.87, 10.31, P = 0.02); however, sub-
stantial heterogeneity (Chi2 = 3.92, df = 1, P = value = 0.05; I2 = 75%) was evident (Fig 4). Data
are presented here as a sensitivity analysis was not possible with only two studies included. The
final meta-analysis synthesising CSHQ data from two studies [19, 20] demonstrated a statisti-
cally significant behavioural intervention effect when compared to control (-4.71, 95% CI -6.70,
-2.73, P<0.00001), with no evidence of statistical heterogeneity (I2 = 0%) (Fig 5).
Risk of bias
Randomisation processes were well described in all studies and as such random sequence gen-
eration risk of bias was low for all studies (see Table 2). Allocation concealment was considered
to be of a low risk of bias for two studies [19, 20] and unclear in the remaining study [17] due
to absence of reporting. It was not possible to blind participants to which arm of the interven-
tion they had been randomised to, hence, all studies were considered to be high risk of bias for
the category ‘blinding of participants and personnel’. The assessment of risk of bias for the
domain ‘blinding of outcome assessment’ is presented separately for parent-reported CSHQ
and the more objective actigraphy measure. The actigraphy data from the Adkins et al. [17]
study was uploaded to a database for centralized scoring, by a single individual who had no
contact with participants. There was no information available for the Cortesi et al. [19] study.
It was considered that there could be a higher risk of bias for the CSHQ, as parents were the
first line assessors, subjectively scoring their children’s sleep behaviours. Again data processing
procedures were not described. The risk of bias for ‘Incomplete outcome data’ was considered
high in the Papadopoulos et al. [20] study, with only 75% of intervention group and 73% of
usual care group providing follow up data. All studies were considered to have low risk of bias
for ‘selective outcome reporting’ as all measures described were reported in the results section.
Discussion
The aim of this review was to systematically review and quantify the effects of behavioural
interventions targeting sleep problems in children with ASD. Three studies evaluating the
effect of behavioural interventions on sleep outcomes in children with ASD were retrieved.
One of the studies [17] provided actigraphy data, one total scores for CSHQs [20], and one
study [19] reported both actigraphy and CSHQ data.
Synthesised actigraphy data showed a statistically significant effect of behavioural interven-
tions compared to control on children’s total sleep time (24 minutes), sleep onset latency (-18
minutes) and sleep efficiency (5.5%). Substantial heterogeneity was evident in the pooled anal-
ysis of the sleep efficiency data; the reason for this was not clear, so data were still presented.
The final meta-analysis combining CSHQ total scores from two studies were in agreement
with the actigraphy results, demonstrating a significant intervention effect (-4.7 CSHQ score)
when compared to non-intervention comparison groups.
Discussion of findings
The interventions in the included studies aimed to educate parents with strategies to improve
sleep behaviours in their children, which is considered the best evidence-based practice in this
population [23]. The depth of descriptions of the interventions included within the primary
papers varied, with Papadopoulos et al. [20] providing the most information. Components of
the behavioural intervention described by Papadopoulos et al. [20], such as emphasizing a
calming bedtime using relaxation training, would be considered effective for many forms of
insomnia, including those related to core deficits of ASD [24]. Cortesi et al. [19] provided an
outline of each of the sessions. The Adkins et al. [17] study reported six areas relevant to pro-
moting sleep among children with ASD provided within the pamphlet in the Adkins et al. [17]
study. It was, however, clear from the information available that the interventions were all
quite different from one another with regards to content and ‘dose’, which should be explored
further.
The summary effect for total sleep duration and sleep onset delay demonstrated statistically
significant differences favouring the intervention groups. Only one [19] of the included origi-
nal studies reported a significant effect post-intervention. This study had the largest sample
size and was the only included study in which children were free from medication. Despite
children in the two smaller studies [17, 20] being on one or more medications, a promising
treatment effect was still observed post intervention. In addition to establishing the effective-
ness of behavioural interventions for insomnia in a drug free population, future research
should explore this in the presence of medications, as it is estimated that 30%–65% of children
with ASD use at least one psychotropic medication [25].
Both of the included actigraphy studies [17, 19] reported a significant intervention effect for
sleep efficiency. The improvement in the original pamphlet study [17] was only a two percent-
age point absolute change, from 75% to 77%, which is unlikely to be clinically meaningful.
This was larger in the Cortesi et al. [19] study (8%) and the between groups difference pre-
sented here was 5.5%, which may be clinically meaningful for some participants. Different
delivery formats warrant further investigation as, in agreement with Kilpatrick [9], this review
indicates that both face-to-face CBT and a more simple information pamphlet are effective in
this population. The individual point estimate from the meta-analysis presented here indicated
a positive post intervention effect for the Adkins et al. [17] study, which was only a two week
self-administered pamphlet.
The CSHQ total score between-groups difference favoured the intervention and was statis-
tically significant. It is difficult to determine if this is clinically meaningful, as the CSHQ was
developed to classify sleep (e.g. a total score of 41 is considered the optimal clinical cut-off for
sleep disturbance; [18]) and as such should be used in conjunction with other sleep measures
when evaluating interventions.
Risk of bias was low across several key domains (randomisation, allocation concealment
and reporting) with some studies being unclear due to poor reporting. There were some
domains where it was difficult to eliminate potential for bias due to study design; for example,
blinding of participants and personnel. Whilst it is unlikely this would directly influence the
children’s actigraphy data, risk of bias may influence parents’ reporting for the CSHQs and
diaries that were kept in conjunction with the actigraphy data. In addition to this, parents
would not have been blinded to outcome assessment when completing CSHQs.
Previous reviews [1, 7–9] have included a broader range of studies to provide a comprehen-
sive overview. However, by including studies with different designs, intervention types and
participant characteristics, it has not been possible to draw definitive conclusions quantifying
intervention effects. A recent review [26] suggests a transdiagnostic treatment approach across
different developmental orders may be effective; however, they conclude more research is
needed prior to any recommendations being made. In comparison, this review had a narrow
focus to begin refining the evidence in this area by statistically quantifying the effects of beha-
vioural interventions in children with ASD. Future research should also consider focusing on
children with ASD and not grouping them with other ‘developmental disorders’ as previous
studies (blindness, Down syndrome in [27]) have done, as children with different conditions
would likely respond differently to behavioural interventions. This is particularly relevant
when considering sleep problem behaviours in children with ASD.
Implications
The evidence presented in the current review will be useful for clinical practice in the manage-
ment of sleep problems in children with ASD, enabling clinicians and families to make
informed choices. Despite behavioural interventions being the recommended first line treat-
ment, and sleep medication being associated with lower quality-of-life scales and more chal-
lenging daytime behaviours, pharmacological prescribing is common with many children
being prescribed more than one type of sleep medication [25]. Behavioural interventions are
advantageous as they are preferred by parents and have positive effects on sleep difficulties in
ASD without the risk of adverse effects associated with pharmacological approaches [12].
Behavioural interventions also have the additional advantage that they can be delivered for
long periods of time if required, and in case of relapse, without concerns about untoward
effects associated with long term use of medication.
Here we provide preliminary quantitative evidence of the effectiveness of behavioural inter-
ventions for treating sleep problems in children with ASD. Future research should explore the
effect of behavioural interventions alone and in combination with other medications in chil-
dren with ASD.
In preparing this review it was evident that interventions targeting sleep problems is a rap-
idly evolving area of research. This review has presented all available evidence to date, how-
ever, the authors are aware of at least one ongoing study with a planned completion date of
2023; Telehealth Delivery of Treatment for Sleep Disturbances in Young Children With
Autism Spectrum Disorder [28].
Supporting information
S1 PRISMA Checklist.
(DOC)
S1 Electronic Search Strategy.
(DOCX)
Acknowledgments
We like to acknowledge the support of Tracy McCranor, Clinical Research Manager from Lin-
colnshire Partnership NHS Foundation Trust who had a role in the early development of the
protocol for this systematic review.
Author Contributions
Conceptualization: Christopher Bridle, Niroshan A. Siriwardena, Amulya Nadkarni, Graham
R. Law.
Investigation: Sophie Keogh, Despina Laparidou, Ffion Curtis.
References
1. Vriend JL, Corkum PV, Moon EC, Smith IM. Behavioral Interventions for Sleep Problems in Children
with Autism Spectrum Disorders: Current Findings and Future Directions. J Pediatr Psychol. 2011 Oct;
36(9): 1017–1029. https://doi.org/10.1093/jpepsy/jsr044 PMID: 21745808
2. World Health Organisation (WHO), Autism spectrum disorders Fact Sheet. Updated 2017. Available
from: https://www.who.int/news-room/fact-sheets/detail/autism-spectrum-disorders
3. Ming X, Brimacombe M, Chaaban J, Zimmerman-Bier B, Wagner GC. Autism spectrum disorders: con-
current clinical disorders. J Child Neurol. 2008; 23(1): 6–13. https://doi.org/10.1177/
0883073807307102 PMID: 18056691
4. Richdale AL, Schreck KA. Sleep problems in autism spectrum disorders: prevalence, nature, & possible
biopsychosocial aetiologies. Sleep Med Rev. 2009; 13(6): 403–411. https://doi.org/10.1016/j.smrv.
2009.02.003 PMID: 19398354
5. Schreck KA, Mulick J, Smith AF. Sleep problems as possible predictors of intensified symptoms of
autism. Res Dev Disabil, 2004 Feb; 25(1):57–66. PMID: 14733976
6. Malow BA, Adkins KW, Reynolds A, Weiss SK, Loh A, Fawkes D, et al. Parent-Based Sleep Education
for Children with Autism Spectrum Disorders. J Autism Dev Disord, 2014 June; 44: 216–228. https://
doi.org/10.1007/s10803-013-1866-z PMID: 23754339
7. Cuomo BM, Vaz S, Lee E, Thompson C, Rogerson JM, Falkmer T. Effectiveness of Sleep-Based Inter-
ventions for Children with Autism Spectrum Disorder: A Meta-Synthesis. Pharmacotherapy. 2017; 37
(5): 555–578. https://doi.org/10.1002/phar.1920 PMID: 28258648
8. Turner KS, Johnson CR. Behavioral Interventions to Address Sleep Disturbances in Children with
Autism Spectrum Disorders: A Review. TECSE, 2012; 33(3): 144–152.
9. Kirkpatrick B, Louw JS, Leader G. Efficacy of parent training incorporated in behavioral sleep interven-
tions for children with autism spectrum disorder and/or intellectual disabilities: a systematic review.
Sleep Med. 2019; 53: 141–152. https://doi.org/10.1016/j.sleep.2018.08.034 PMID: 30529483
10. Abbott SM, Knutson KL, Zee PC. Health implications of sleep and circadian rhythm research in 2017.
Lancet Neurol. 2018 Jan; 17(1): 17–18. https://doi.org/10.1016/S1474-4422(17)30410-6 PMID:
29262995
11. Johnson CR, Turner KS, Foldes E, Brooks MB, Kronk R, Wiggs L. Behavioral parent training to address
sleep disturbances in young children with autism spectrum disorder: a pilot trial. Sleep Med. 2013 Oct;
14(10): 995–1004. https://doi.org/10.1016/j.sleep.2013.05.013 PMID: 23993773
12. Rossignol DA, Frye RE. Melatonin in autism spectrum disorders: a systematic review and meta-analy-
sis. Dev Med Child Neurol. 2011 April; 53(9): 783–792. https://doi.org/10.1111/j.1469-8749.2011.
03980.x PMID: 21518346
13. National Institute for Health and Care Excellence (2013) Autism spectrum disorder in under 19s: sup-
port and management, Clinical guideline [CG170]. Available at: https://www.nice.org.uk/guidance/
cg170/chapter/1-Recommendations [Accessed 24 May 2019].
14. Goodday A, Corkum P, Smith IM. Parental Acceptance of Treatments for Insomnia in Children with
Attention-Deficit/Hyperactivity Disorder, Autistic Spectrum Disorder, and their Typically Developing
Peers. Children’s Health Care. 2013 Oct; 43(1): 54–71.
15. Moher D, Liberati A, Tetzlaff J, Altman GD. Preferred Reporting Items for Systematic Reviews and
Meta-Analyses: The PRISMA Statement. PLoS Med, 2009; 6(7): e1000097. https://doi.org/10.1371/
journal.pmed.1000097 PMID: 19621072
16. Review Manager (RevMan) [Computer program]. Version 5.3. Copenhagen: The Nordic Cochrane
Centre, The Cochrane Collaboration, 2014.
17. Adkins KW, Molloy C, Weiss SK, Reynolds A, Goldman SE, Burnette C, et al. Effects of a Standardized
Pamphlet on Insomnia in Children with Autism Spectrum Disorders. Paediatrics. 2012; 130(2): S139–S144.
18. Owens JA, Spirito A, McGuinn M. The children’s sleep habits questionnaire (cshq): Psychometric prop-
erties of a survey instrument for school-aged children. Sleep. 2000; 23: 1043–1051. PMID: 11145319
19. Cortesi F, Giannotti F, Sebastiani TE, Panunzi S, Valente DE. Controlled-release melatonin, singly and
combined with cognitive behavioural therapy, for persistent insomnia in children with autism spectrum
disorders: a randomized placebo-controlled trial. J. Sleep Res. 2012 May; 21(6): 700–709. https://doi.
org/10.1111/j.1365-2869.2012.01021.x PMID: 22616853
20. Papadopoulos N, Sciberras E, Hiscock H, Mulraney M, McGillivray J, Rinehart N. The Efficacy of a Brief
Behavioral Sleep Intervention in School-Aged Children with ADHD and Comorbid Autism Spectrum Dis-
order. J Atten Disord. 2015 Feb. https://doi.org/10.1177/1087054714568565
21. Dı́az-Román A, Zhang J, Delorme R, Beggiato A, Cortese S. Sleep in youth with autism spectrum disor-
ders: systematic review and meta-analysis of subjective and objective studies. Evid Based Ment Health.
2018; 21(4): 16–154.
22. Moore M, Evans V, Hanvey G, Johnson C. Assessment of Sleep in Children with Autism Spectrum Dis-
order. Children. 2017; 4(8): 72. https://doi.org/10.3390/children4080072 PMID: 28786962
23. McDowall PS, Galland BC, Campbell AJ, Elder DE. Parent knowledge of children’s sleep: A systematic
review. Sleep Med Rev. 2017 Feb; 31: 39–47. https://doi.org/10.1016/j.smrv.2016.01.002 PMID:
26899741
24. Malow BA, Katz T, Reynolds AM, Shui A, Carno M, Connolly HV, et al. Sleep Difficulties and Medica-
tions in Children with Autism Spectrum Disorders: A Registry Study. Pediatrics. 2016; 137(2): S98–
S104. https://doi.org/10.1542/peds.2015-2851H PMID: 26908483
25. Schubart JR, Camacho F, Leslie D. Psychotropic medication trends among children and adolescents
with autism spectrum disorder in the Medicaid program. Autism. 2014 Oct; 18(6): 631–637. https://doi.
org/10.1177/1362361313497537 PMID: 24165274
26. Rigney G, Ali NS, Corkum PV, Brown CA, Constantin E, Godbout R. et al. A systematic review to
explore the feasibility of a behavioural sleep intervention for insomnia in children with neurodevelop-
mental disorders: A transdiagnostic approach. Sleep Med Rev. 2018 Oct; 41: 244–254. https://doi.org/
10.1016/j.smrv.2018.03.008 PMID: 29764710
27. Moss AHB, Gordon JE, O’Connell A. Impact of Sleepwise: An Intervention for Youth with Developmen-
tal Disabilities and Sleep Disturbance. J Autism Dev Disord, 2014 Jan; 44(7): 1695–1707. https://doi.
org/10.1007/s10803-014-2040-y PMID: 24442795
28. ClinicalTrials.gov. [internet] National Library of Medicine (US). Identifier: NCT03668873. Telehealth
Delivery of Treatment for Sleep Disturbances in Young Children With Autism Spectrum Disorder. Avail-
able at: https://clinicaltrials.gov/ct2/show/NCT03668873